<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Malar J</journal-id><journal-title>Malaria Journal</journal-title><issn pub-type="epub">1475-2875</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16179089</article-id><article-id pub-id-type="pmc">1261533</article-id><article-id pub-id-type="publisher-id">1475-2875-4-46</article-id><article-id pub-id-type="doi">10.1186/1475-2875-4-46</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>A randomized trial of artemether-lumefantrine <italic>versus </italic>mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant <italic>Plasmodium falciparum </italic>on the western border of Thailand</article-title></title-group><contrib-group><contrib id="A1" equal-contrib="yes" contrib-type="author"><name><surname>Hutagalung</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>robert@shoklo-unit.com</email></contrib><contrib id="A2" equal-contrib="yes" contrib-type="author"><name><surname>Paiphun</surname><given-names>Lucy</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>lucy@shoklo-unit.com</email></contrib><contrib id="A3" equal-contrib="yes" contrib-type="author"><name><surname>Ashley</surname><given-names>Elizabeth A</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>e.ashley@another.com</email></contrib><contrib id="A4" equal-contrib="yes" contrib-type="author"><name><surname>McGready</surname><given-names>Rose</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>rose@shoklo-unit.com</email></contrib><contrib id="A5" equal-contrib="yes" contrib-type="author"><name><surname>Brockman</surname><given-names>Alan</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>Alan.Brockman@menzies.edu.au</email></contrib><contrib id="A6" equal-contrib="yes" contrib-type="author"><name><surname>Thwai</surname><given-names>Kaw L</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>klthwai@yahoo.co.uk</email></contrib><contrib id="A7" equal-contrib="yes" contrib-type="author"><name><surname>Singhasivanon</surname><given-names>Pratap</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>tmpsh@mucc.mahidol.ac.th</email></contrib><contrib id="A8" equal-contrib="yes" contrib-type="author"><name><surname>Jelinek</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>jelinek@bbges.de</email></contrib><contrib id="A9" equal-contrib="yes" contrib-type="author"><name><surname>White</surname><given-names>Nicholas J</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>nickwdt@tropmedres.ac</email></contrib><contrib id="A10" equal-contrib="yes" corresp="yes" contrib-type="author"><name><surname>Nosten</surname><given-names>François H</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>SMRU@tropmedres.ac</email></contrib></contrib-group><aff id="I1"><label>1</label>Shoklo Malaria Research Unit, Mae Sod, Tak Province, Thailand</aff><aff id="I2"><label>2</label>Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand</aff><aff id="I3"><label>3</label>Centre for Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Headington, Oxford, UK</aff><aff id="I4"><label>4</label>Menzies School of Health Research, Darwin, NT, Australia</aff><aff id="I5"><label>5</label>Institut für Tropenmedizin, Berlin, Germany</aff><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>22</day><month>9</month><year>2005</year></pub-date><volume>4</volume><fpage>46</fpage><lpage>46</lpage><ext-link ext-link-type="uri" xlink:href="http://www.malariajournal.com/content/4/1/46"></ext-link><history><date date-type="received"><day>16</day><month>7</month><year>2005</year></date><date date-type="accepted"><day>22</day><month>9</month><year>2005</year></date></history><permissions><copyright-statement>Copyright © 2005 Hutagalung et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2005</copyright-year><copyright-holder>Hutagalung et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="5280" xml_f="5290" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="5301" xml_f="5418" txt_i="22" txt_f="139">The use of antimalarial drug combinations with artemisinin derivatives is recommended to overcome drug resistance in </offsets><italic><offsets xml_i="5426" xml_f="5447" txt_i="139" txt_f="160">Plasmodium falciparum</offsets></italic><offsets xml_i="5456" xml_f="5852" txt_i="160" txt_f="556">. The fixed combination of oral artemether-lumefantrine, an artemisinin combination therapy (ACT) is highly effective and well tolerated. It is the only registered fixed combination containing an artemisinin. The trial presented here was conducted to monitor the efficacy of the six-dose regimen of artemether-lumefantrine (ALN) in an area of multi-drug resistance, along the Thai-Myanmar border.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="5893" xml_f="5900" txt_i="558" txt_f="565">Methods</offsets></title><p><offsets xml_i="5911" xml_f="6219" txt_i="566" txt_f="874">The trial was an open-label, two-arm, randomized study comparing artemether-lumefantrine and mefloquine-artesunate for the treatment of uncomplicated falciparum malaria with 42 days of follow up. Parasite genotyping by polymerase chain reaction (PCR) was used to distinguish recrudescent from newly acquired </offsets><italic><offsets xml_i="6227" xml_f="6241" txt_i="874" txt_f="888">P. falciparum </offsets></italic><offsets xml_i="6250" xml_f="6326" txt_i="888" txt_f="964">infections. The PCR adjusted cure rates were evaluated by survival analysis.</offsets></p></sec><sec><title><offsets xml_i="6348" xml_f="6355" txt_i="966" txt_f="973">Results</offsets></title><p><offsets xml_i="6366" xml_f="6438" txt_i="974" txt_f="1046">In 2001–2002 a total of 490 patients with slide confirmed uncomplicated </offsets><italic><offsets xml_i="6446" xml_f="6460" txt_i="1046" txt_f="1060">P. falciparum </offsets></italic><offsets xml_i="6469" xml_f="6978" txt_i="1060" txt_f="1569">malaria were randomly assigned to receive artemether-lumefantrine (n = 245) or artesunate and mefloquine (n = 245) and were followed for 42 days. All patients had rapid initial clinical and parasitological responses. In both groups, the PCR adjusted cure rates by day 42 were high: 98.8% (95% CI 96.4, 99.6%) for artemether-lumefantrine and 96.3% (95% CI 93.1, 98.0%) for artesunate-mefloquine. Both regimens were very well tolerated with no serious adverse events observed attributable to either combination.</offsets></p></sec><sec><title><offsets xml_i="7000" xml_f="7010" txt_i="1571" txt_f="1581">Conclusion</offsets></title><p><offsets xml_i="7021" xml_f="7228" txt_i="1582" txt_f="1789">Overall, this study confirms that these two artemisinin-based combinations remain highly effective and result in equivalent therapeutic responses in the treatment of highly drug-resistant falciparum malaria.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="7290" xml_f="7302" txt_i="1798" txt_f="1810">Introduction</offsets></title><p><offsets xml_i="7313" xml_f="7338" txt_i="1811" txt_f="1836">Multi-drug resistance of </offsets><italic><offsets xml_i="7346" xml_f="7368" txt_i="1836" txt_f="1858">Plasmodium falciparum </offsets></italic><offsets xml_i="7377" xml_f="7498" txt_i="1858" txt_f="1979">is a major health problem in many countries and the number of drugs available, effective and affordable is very limited [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="7529" xml_f="7530" txt_i="1979" txt_f="1980">1</offsets></xref><offsets xml_i="7537" xml_f="7571" txt_i="1980" txt_f="2014">]. Along the Thai-Myanmar border, </offsets><italic><offsets xml_i="7579" xml_f="7593" txt_i="2014" txt_f="2028">P. falciparum </offsets></italic><offsets xml_i="7602" xml_f="7666" txt_i="2028" txt_f="2092">has developed resistance to almost all available antimalarials [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="7697" xml_f="7698" txt_i="2092" txt_f="2093">2</offsets></xref><offsets xml_i="7705" xml_f="7840" txt_i="2093" txt_f="2228">]. As in tuberculosis and HIV where resistance to drugs is a serious issue, combination therapy has been applied to malaria treatment [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="7871" xml_f="7872" txt_i="2228" txt_f="2229">3</offsets></xref><offsets xml_i="7879" xml_f="8014" txt_i="2229" txt_f="2364">]. The use of antimalarial drug combinations with artemisinin derivatives has been advocated and is now implemented in many countries [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="8045" xml_f="8046" txt_i="2364" txt_f="2365">4</offsets></xref><offsets xml_i="8053" xml_f="8160" txt_i="2365" txt_f="2472">]. An extensive amount of information on efficacy and safety of mefloquine has been reported and reviewed [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="8191" xml_f="8192" txt_i="2472" txt_f="2473">5</offsets></xref><offsets xml_i="8199" xml_f="8271" txt_i="2473" txt_f="2545">]. Artemisinin or Qinghaosu is an extract of the medical plant Qinghao (</offsets><italic><offsets xml_i="8279" xml_f="8294" txt_i="2545" txt_f="2560">Artemisia annua</offsets></italic><offsets xml_i="8303" xml_f="8421" txt_i="2560" txt_f="2678">), which together with its derivatives, artesunate and artemether are the most active antimalarial compounds to date [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="8452" xml_f="8453" txt_i="2678" txt_f="2679">6</offsets></xref><offsets xml_i="8460" xml_f="8616" txt_i="2679" txt_f="2835">]. The artemisinin derivatives have a rapid onset of therapeutic effect, where a single dose can reduce the parasite biomass by a factor of approximately 10</offsets><sup><offsets xml_i="8621" xml_f="8623" txt_i="2835" txt_f="2837">4 </offsets></sup><offsets xml_i="8629" xml_f="8734" txt_i="2837" txt_f="2942">every 48 hours. In addition, they have a very short terminal elimination half-life of less than 2 hours [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="8765" xml_f="8766" txt_i="2942" txt_f="2943">7</offsets></xref><offsets xml_i="8773" xml_f="8924" txt_i="2943" txt_f="3094">]. Previous studies showed that once-daily administration with artemisinin derivatives produced equivalent cure rates to more frequent administration [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="8955" xml_f="8956" txt_i="3094" txt_f="3095">8</offsets></xref><offsets xml_i="8963" xml_f="9084" txt_i="3095" txt_f="3216">]. A three-day course of artesunate combined with high dose mefloquine has become the standard treatment combination for </offsets><italic><offsets xml_i="9092" xml_f="9106" txt_i="3216" txt_f="3230">P. falciparum </offsets></italic><offsets xml_i="9115" xml_f="9139" txt_i="3230" txt_f="3254">infections in Thailand [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="9170" xml_f="9171" txt_i="3254" txt_f="3255">9</offsets></xref><offsets xml_i="9178" xml_f="9509" txt_i="3255" txt_f="3586">]. Oral artesunate-mefloquine is the most widely used combination. More recently, a fixed combination of oral artemether-lumefantrine (formerly known as benflumetol) has become available. Artemether is a methyl-ether derivative of artemisinin. Lumefantrine is a racemic fluorine derivative with high blood schizontocidal activity [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="9541" xml_f="9543" txt_i="3586" txt_f="3588">10</offsets></xref><offsets xml_i="9550" xml_f="9639" txt_i="3588" txt_f="3677">]. Both artemisinin combination therapies (ACT) are highly effective and well tolerated [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="9671" xml_f="9673" txt_i="3677" txt_f="3679">11</offsets></xref><offsets xml_i="9680" xml_f="10074" txt_i="3679" txt_f="4073">]. However, resistance to mefloquine and/or to lumefantrine, would compromise both combinations. Therefore it is important to monitor the therapeutic efficacy and thus provide advance warning in case of change. The trial presented here was conducted to monitor the efficacy of the six-dose regimen of artemether-lumefantrine combination given over three days for the treatment of uncomplicated </offsets><italic><offsets xml_i="10082" xml_f="10096" txt_i="4073" txt_f="4087">P. falciparum </offsets></italic><offsets xml_i="10105" xml_f="10173" txt_i="4087" txt_f="4155">infections in adults and children on the western border of Thailand.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="10214" xml_f="10234" txt_i="4157" txt_f="4177">Patients and methods</offsets></title><p><offsets xml_i="10245" xml_f="10608" txt_i="4178" txt_f="4541">This study was conducted in the Maela and Mawker Tai malaria clinics of the Shoklo Malaria Research Unit (Mae Sot, Thailand)between July 2001 and June 2002. Patients were recruited from two populations: displaced people of the Karen ethnic minority and migrant workers living on the western border of Thailand. This is an area of low and unstable transmission of </offsets><italic><offsets xml_i="10616" xml_f="10633" txt_i="4541" txt_f="4558">Plasmodium vivax </offsets></italic><offsets xml_i="10642" xml_f="10667" txt_i="4558" txt_f="4583">and multi-drug-resistant </offsets><italic><offsets xml_i="10675" xml_f="10689" txt_i="4583" txt_f="4597">P. falciparum </offsets></italic><offsets xml_i="10698" xml_f="10699" txt_i="4597" txt_f="4598">[</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="10731" xml_f="10733" txt_i="4598" txt_f="4600">12</offsets></xref><offsets xml_i="10740" xml_f="10979" txt_i="4600" txt_f="4839">]. The trial was an open-label, two-arm, randomized study comparing artemether-lumefantrine andmefloquine-artesunate. This study was approved by the Ethical and Scientific Committees of the Faculty of Tropical Medicine, Mahidol University.</offsets></p><sec sec-type="methods"><title><offsets xml_i="11014" xml_f="11024" txt_i="4840" txt_f="4850">Procedures</offsets></title><p><offsets xml_i="11035" xml_f="11094" txt_i="4851" txt_f="4907">Patients &gt;10 kg in weight who had slide-confirmed acute </offsets><italic><offsets xml_i="11102" xml_f="11116" txt_i="4907" txt_f="4921">P. falciparum </offsets></italic><offsets xml_i="11125" xml_f="11448" txt_i="4921" txt_f="5244">malaria were included in the study, provided that they or their guardians gave fully informed written consent intheir own language, they were not pregnant, they had not received mefloquine in the previous 63 days and there were no other clinical or laboratory signs of severe illness and/or severe and complicated malaria [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="11480" xml_f="11482" txt_i="5244" txt_f="5246">13</offsets></xref><offsets xml_i="11489" xml_f="11634" txt_i="5246" txt_f="5391">]. If they gave written informed consent, they were allocated randomly to receive either the six-dose regimen of artemether-lumefantrine (Coartem</offsets><sup><offsets xml_i="11639" xml_f="11641" txt_i="5391" txt_f="5393">® </offsets></sup><offsets xml_i="11647" xml_f="11716" txt_i="5393" txt_f="5462">20/120, Novartis Pharma AG, Basel, Switzerland) or mefloquine (Lariam</offsets><sup><offsets xml_i="11721" xml_f="11722" txt_i="5462" txt_f="5463">®</offsets></sup><offsets xml_i="11728" xml_f="12660" txt_i="5463" txt_f="6395">, Hoffman-La Roche, Basel, Switzerland) plus artesunate (Guilin Pharmaceutical Factory No.1, Guilin, China). At enrolment (Day 0), a medical history was obtained, a full physical examination was performed and blood was taken for quantitative parasite counts and routine haematology (finger prick blood sample for malaria smear and haematocrit). All information was recorded on a standard case record form. All patients were examined and blood smears were taken daily until they became aparasitaemic, and then weekly for 6 weeks. At each visit a questionnaire on adverse events was completed. A blood smear was also taken from any patient complaining of fever or symptoms compatible with malaria during the follow-up period. Parasite counts were determined on Giemsa-stained thick and thin blood films. The person-gametocyte-weeks were calculated per 1,000 person-weeks after excluding the episodes on admission and during treatment.</offsets></p></sec><sec><title><offsets xml_i="12682" xml_f="12695" txt_i="6397" txt_f="6410">Drug regimens</offsets></title><p><offsets xml_i="12706" xml_f="13557" txt_i="6411" txt_f="7262">Computerized randomization was in blocks of ten. Patients allocated to artemether-lumefantrine group (ALN) received the tablets at 0 and 8 hours and twice daily for the following 2 days. Artemether-lumefantrine was dispensed as a fixed dose combination tablet. Each tablet contained 20 mg of artemether and 120 mg of lumefantrine. The number of tablets was given according to the body weight. The minimum dosage for patients weighing less than 15 kg was one tablet per dose; patients between 15 and 24 kg received two tablets, those between 25 and 34 kg received three tablets and patients 35 kg and above were treated with four tablets per dose. Patients allocated to artesunate-mefloquine group (MAS3) received artesunate, 4 mg/kg oncedaily for 3 days (day 0 was the first day of treatment), plus mefloquine, 15 mg/kg on day 1 and 10 mg/kg on day 2.</offsets></p><p><offsets xml_i="13564" xml_f="14055" txt_i="7263" txt_f="7754">Each patient was given antipyretics and cooled by tepid sponging if the tympanic temperature was equal or above 37.5°C before drug administration. Drug administration was observed in all patients and if vomiting occurred in less than 30 min, administration of the full dose was repeated, if vomiting occurred between 30 and 60 min, half the dose was repeated. Patients treated with artemether-lumefantrine were given a glass of chocolate milk (200 ml) with each dose to increase absorption [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="14087" xml_f="14089" txt_i="7754" txt_f="7756">14</offsets></xref><offsets xml_i="14096" xml_f="14098" txt_i="7756" txt_f="7758">].</offsets></p></sec><sec><title><offsets xml_i="14120" xml_f="14136" txt_i="7760" txt_f="7776">Outcome measures</offsets></title><p><offsets xml_i="14147" xml_f="14441" txt_i="7777" txt_f="8071">The primary therapeutic outcome measure in this study was the incidence of microscopically and genotypically confirmedrecrudescent infections in both treatment groups by day 42. Parasite genotyping by the polymerase chain reaction (PCR) was used to distinguish recrudescent from newly acquired </offsets><italic><offsets xml_i="14449" xml_f="14463" txt_i="8071" txt_f="8085">P. falciparum </offsets></italic><offsets xml_i="14472" xml_f="14484" txt_i="8085" txt_f="8097">infections. </offsets><italic><offsets xml_i="14492" xml_f="14506" txt_i="8097" txt_f="8111">P. falciparum </offsets></italic><offsets xml_i="14515" xml_f="14738" txt_i="8111" txt_f="8334">infections were genotyped for allelic variation in three polymorphic antigen loci, merozoite surface proteins 1 and 2 (MSP-1 and MSP-2) and glutamate rich protein (GLURP), on admission and in case of parasite reappearance [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="14770" xml_f="14772" txt_i="8334" txt_f="8336">15</offsets></xref><offsets xml_i="14779" xml_f="14780" txt_i="8336" txt_f="8337">,</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="14812" xml_f="14814" txt_i="8337" txt_f="8339">16</offsets></xref><offsets xml_i="14821" xml_f="15126" txt_i="8339" txt_f="8644">]. Secondary measures were the immediate treatment responses: parasite clearance, fever clearance, incidence of adverse events, and degree of anaemia. The sample size was calculated to detect a difference in failure rates of 7 % between the two regimens with 90% CI and 80 % power assuming a 20% drop out.</offsets></p></sec><sec><title><offsets xml_i="15148" xml_f="15162" txt_i="8646" txt_f="8660">Adverse events</offsets></title><p><offsets xml_i="15173" xml_f="15542" txt_i="8661" txt_f="9027">Adverse events were symptoms or signs that were not presenton admission and that developed after the start of treatment. All adverse events, including those probably related to malaria, were recording and compared among treatment groups. The rates of early vomiting (&lt;1 h) after each dose and for each drug wererecorded and compared among the groups in the analysis.</offsets></p></sec><sec><title><offsets xml_i="15564" xml_f="15601" txt_i="9029" txt_f="9066">Management of recrudescent infections</offsets></title><p><offsets xml_i="15612" xml_f="15795" txt_i="9067" txt_f="9247">Patients with uncomplicated recrudescent infections were re-treated with artesunate, 2 mg/kg/day for 7 days; patients &gt;8 years oldalso received doxycycline, 4 mg/kg/day for 7 days.</offsets></p></sec><sec><title><offsets xml_i="15817" xml_f="15837" txt_i="9249" txt_f="9269">Statistical analysis</offsets></title><p><offsets xml_i="15848" xml_f="16113" txt_i="9270" txt_f="9535">Data were analysed using SPSS for Windows, version 11. Categorical data were compared using the Chi-square test with Yates' correction or by Fisher's exact test, as appropriate. Continuous variables conforming to a normal distribution were compared using Student's </offsets><italic><offsets xml_i="16121" xml_f="16123" txt_i="9535" txt_f="9537">t </offsets></italic><offsets xml_i="16132" xml_f="16224" txt_i="9537" txt_f="9629">test. Data not normally distributed were log-transformed or compared using the Mann-Whitney </offsets><italic><offsets xml_i="16232" xml_f="16234" txt_i="9629" txt_f="9631">U </offsets></italic><offsets xml_i="16243" xml_f="16910" txt_i="9631" txt_f="10298">test. The relative risks were calculated using cross-tabulations. The rates of adverse events at three different periods (days 1–2, days 3–7 and days 14–42) were compared among treatment groups. For each of the three periods, the events were counted only once (e.g., if a patient vomited on day one and day two, this was counted as one adverse event). The PCR-adjusted cure rates were evaluated by survival analysis and compared using the log-rank test. Patients for whom PCR genotyping was either inconclusive or missing were censored in the survival analysis on the day of parasite reappearance. For all statistical tests the significance level (p) was set at 0.05.</offsets></p></sec></sec><sec><title><offsets xml_i="16938" xml_f="16945" txt_i="10301" txt_f="10308">Results</offsets></title><p><offsets xml_i="16956" xml_f="17008" txt_i="10309" txt_f="10361">Four hundred and ninety patients with uncomplicated </offsets><italic><offsets xml_i="17016" xml_f="17030" txt_i="10361" txt_f="10375">P. falciparum </offsets></italic><offsets xml_i="17039" xml_f="17292" txt_i="10375" txt_f="10628">infections were enrolled between July 2001 and May 2002. The artesunate-mefloquine and artemether-lumefantrine groups included 245 patients each, the age range for all patients was 2–72 years. Baseline characteristics were similar in both groups (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="17324" xml_f="17325" txt_i="10628" txt_f="10629">1</offsets></xref><offsets xml_i="17332" xml_f="17831" txt_i="10629" txt_f="11128">). In total, 484 patients (242 each group) were included in the final evaluation. Six patients (three in each group) were excluded for the following reasons; withdrew consent (1), non-compliance e.g. failure to complete trial treatment course (4), failure to meet protocol criteria (1). Overall compliance was good; around 99% of the patients in the study (481 of 484) were seen at the day seven scheduled visit, 96.1% (465 patients) were seen at day 28 and 93.4% (452 patients) were seen at day 42.</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="17879" xml_f="17886" txt_i="11129" txt_f="11136">Table 1</offsets></label><caption><p><offsets xml_i="17906" xml_f="17946" txt_i="11136" txt_f="11176">Demographic and baseline characteristics</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><offsets xml_i="18034" xml_f="18048" txt_i="11178" txt_f="11192">ALN* (n = 245)</offsets></td><td align="left"><offsets xml_i="18070" xml_f="18086" txt_i="11193" txt_f="11209">MAS3** (n = 245)</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="18132" xml_f="18137" txt_i="11210" txt_f="11215">Maela</offsets></td><td align="left"><offsets xml_i="18159" xml_f="18162" txt_i="11216" txt_f="11219">100</offsets></td><td align="left"><offsets xml_i="18184" xml_f="18187" txt_i="11220" txt_f="11223">100</offsets></td></tr><tr><td align="left"><offsets xml_i="18218" xml_f="18228" txt_i="11224" txt_f="11234">Mawker Tai</offsets></td><td align="left"><offsets xml_i="18250" xml_f="18253" txt_i="11235" txt_f="11238">145</offsets></td><td align="left"><offsets xml_i="18275" xml_f="18278" txt_i="11239" txt_f="11242">145</offsets></td></tr><tr><td align="left"><offsets xml_i="18309" xml_f="18323" txt_i="11243" txt_f="11257">Males, no. (%)</offsets></td><td align="left"><offsets xml_i="18345" xml_f="18353" txt_i="11258" txt_f="11266">172 (70)</offsets></td><td align="left"><offsets xml_i="18375" xml_f="18383" txt_i="11267" txt_f="11275">164 (67)</offsets></td></tr><tr><td align="left"><offsets xml_i="18414" xml_f="18424" txt_i="11276" txt_f="11286">Age, years</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="18473" xml_f="18482" txt_i="11289" txt_f="11298">Mean (SD)</offsets></td><td align="left"><offsets xml_i="18504" xml_f="18515" txt_i="11299" txt_f="11310">23.2 (14.6)</offsets></td><td align="left"><offsets xml_i="18537" xml_f="18548" txt_i="11311" txt_f="11322">23.6 (15.1)</offsets></td></tr><tr><td align="left"><offsets xml_i="18579" xml_f="18584" txt_i="11323" txt_f="11328">Range</offsets></td><td align="left"><offsets xml_i="18606" xml_f="18610" txt_i="11329" txt_f="11333">3–70</offsets></td><td align="left"><offsets xml_i="18632" xml_f="18636" txt_i="11334" txt_f="11338">2–72</offsets></td></tr><tr><td align="left"><offsets xml_i="18667" xml_f="18685" txt_i="11339" txt_f="11357">Age group, no. (%)</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="18734" xml_f="18739" txt_i="11360" txt_f="11362">&lt;5</offsets></td><td align="left"><offsets xml_i="18761" xml_f="18769" txt_i="11363" txt_f="11371">10 (4.1)</offsets></td><td align="left"><offsets xml_i="18791" xml_f="18798" txt_i="11372" txt_f="11379">8 (3.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="18829" xml_f="18833" txt_i="11380" txt_f="11384">5–14</offsets></td><td align="left"><offsets xml_i="18855" xml_f="18864" txt_i="11385" txt_f="11394">81 (33.1)</offsets></td><td align="left"><offsets xml_i="18886" xml_f="18895" txt_i="11395" txt_f="11404">75 (30.6)</offsets></td></tr><tr><td align="left"><offsets xml_i="18926" xml_f="18932" txt_i="11405" txt_f="11408">&gt;14</offsets></td><td align="left"><offsets xml_i="18954" xml_f="18964" txt_i="11409" txt_f="11419">154 (62.9)</offsets></td><td align="left"><offsets xml_i="18986" xml_f="18996" txt_i="11420" txt_f="11430">162 (66.1)</offsets></td></tr><tr><td align="left"><offsets xml_i="19027" xml_f="19037" txt_i="11431" txt_f="11441">Weight, kg</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="19086" xml_f="19095" txt_i="11444" txt_f="11453">Mean (SD)</offsets></td><td align="left"><offsets xml_i="19117" xml_f="19128" txt_i="11454" txt_f="11465">42.4 (14.5)</offsets></td><td align="left"><offsets xml_i="19150" xml_f="19161" txt_i="11466" txt_f="11477">42.3 (15.0)</offsets></td></tr><tr><td align="left"><offsets xml_i="19192" xml_f="19197" txt_i="11478" txt_f="11483">Range</offsets></td><td align="left"><offsets xml_i="19219" xml_f="19224" txt_i="11484" txt_f="11489">10–77</offsets></td><td align="left"><offsets xml_i="19246" xml_f="19251" txt_i="11490" txt_f="11495">10–78</offsets></td></tr><tr><td align="left"><offsets xml_i="19282" xml_f="19297" txt_i="11496" txt_f="11511">Temperature, °C</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="19346" xml_f="19355" txt_i="11514" txt_f="11523">Mean (SD)</offsets></td><td align="left"><offsets xml_i="19377" xml_f="19387" txt_i="11524" txt_f="11534">37.7 (1.0)</offsets></td><td align="left"><offsets xml_i="19409" xml_f="19419" txt_i="11535" txt_f="11545">37.8 (1.1)</offsets></td></tr><tr><td align="left"><offsets xml_i="19450" xml_f="19455" txt_i="11546" txt_f="11551">Range</offsets></td><td align="left"><offsets xml_i="19477" xml_f="19486" txt_i="11552" txt_f="11561">35.6–40.5</offsets></td><td align="left"><offsets xml_i="19508" xml_f="19517" txt_i="11562" txt_f="11571">35.9–41.0</offsets></td></tr><tr><td align="left"><offsets xml_i="19548" xml_f="19553" txt_i="11572" txt_f="11577">Fever</offsets><sup><offsets xml_i="19558" xml_f="19559" txt_i="11577" txt_f="11578">a</offsets></sup><offsets xml_i="19565" xml_f="19573" txt_i="11578" txt_f="11586">, no (%)</offsets></td><td align="left"><offsets xml_i="19595" xml_f="19605" txt_i="11587" txt_f="11597">136 (55.5)</offsets></td><td align="left"><offsets xml_i="19627" xml_f="19637" txt_i="11598" txt_f="11608">142 (58.0)</offsets></td></tr><tr><td align="left"><offsets xml_i="19668" xml_f="19682" txt_i="11609" txt_f="11623">Haematocrit, %</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="19731" xml_f="19740" txt_i="11626" txt_f="11635">Mean (SD)</offsets></td><td align="left"><offsets xml_i="19762" xml_f="19772" txt_i="11636" txt_f="11646">36.7 (5.9)</offsets></td><td align="left"><offsets xml_i="19794" xml_f="19804" txt_i="11647" txt_f="11657">36.4 (5.8)</offsets></td></tr><tr><td align="left"><offsets xml_i="19835" xml_f="19840" txt_i="11658" txt_f="11663">Range</offsets></td><td align="left"><offsets xml_i="19862" xml_f="19867" txt_i="11664" txt_f="11669">21–52</offsets></td><td align="left"><offsets xml_i="19889" xml_f="19894" txt_i="11670" txt_f="11675">20–51</offsets></td></tr><tr><td align="left"><offsets xml_i="19925" xml_f="19947" txt_i="11676" txt_f="11698">Geometric mean (range)</offsets></td><td align="left"><offsets xml_i="19969" xml_f="19974" txt_i="11699" txt_f="11704">8,047</offsets></td><td align="left"><offsets xml_i="19996" xml_f="20001" txt_i="11705" txt_f="11710">7,570</offsets></td></tr><tr><td align="left"><offsets xml_i="20032" xml_f="20050" txt_i="11711" txt_f="11729">parasite count (μl</offsets><sup><offsets xml_i="20055" xml_f="20057" txt_i="11729" txt_f="11731">-1</offsets></sup><offsets xml_i="20063" xml_f="20064" txt_i="11731" txt_f="11732">)</offsets></td><td align="left"><offsets xml_i="20086" xml_f="20098" txt_i="11733" txt_f="11745">(32–198,789)</offsets></td><td align="left"><offsets xml_i="20120" xml_f="20132" txt_i="11746" txt_f="11758">(16–198,789)</offsets></td></tr><tr><td align="left"><offsets xml_i="20163" xml_f="20183" txt_i="11759" txt_f="11779">Hepatomegaly, no (%)</offsets></td><td align="left"><offsets xml_i="20205" xml_f="20214" txt_i="11780" txt_f="11789">48 (19.6)</offsets></td><td align="left"><offsets xml_i="20236" xml_f="20245" txt_i="11790" txt_f="11799">50 (20.4)</offsets></td></tr><tr><td align="left"><offsets xml_i="20276" xml_f="20296" txt_i="11800" txt_f="11820">Splenomegaly, no (%)</offsets></td><td align="left"><offsets xml_i="20318" xml_f="20327" txt_i="11821" txt_f="11830">70 (28.6)</offsets></td><td align="left"><offsets xml_i="20349" xml_f="20358" txt_i="11831" txt_f="11840">57 (23.3)</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="20404" xml_f="20469" txt_i="11841" txt_f="11906">* ALN = artemether-lumefantrine, ** MAS3 = artesunate-mefloquine </offsets><sup><offsets xml_i="20474" xml_f="20475" txt_i="11906" txt_f="11907">a</offsets></sup><offsets xml_i="20481" xml_f="20510" txt_i="11907" txt_f="11936">Tympanic temperature ≥ 37.5°C</offsets></p></table-wrap-foot></table-wrap><sec><title><offsets xml_i="20557" xml_f="20594" txt_i="11937" txt_f="11974">Clinical and parasitological findings</offsets></title><p><offsets xml_i="20605" xml_f="21036" txt_i="11975" txt_f="12406">The initial responses to the two treatment groups were similar. None of the patients developed severe malaria. On admission, 55.0% (133/242) of the patients on ALN and 57.9% (140/242) of the patients in the MAS3 group had a tympanic temperature ≥ 37.5°C. All except three patients had a normal temperature on day 3 (2 in ALN and 1 in MAS3). There was no difference in fever clearance times between the two treatment groups (Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="21066" xml_f="21067" txt_i="12406" txt_f="12407">1</offsets></xref><offsets xml_i="21074" xml_f="21177" txt_i="12407" txt_f="12510">). Parasite clearance times were short and most patients cleared their parasitaemia by day two. Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="21207" xml_f="21208" txt_i="12510" txt_f="12511">2</offsets></xref><offsets xml_i="21215" xml_f="21281" txt_i="12511" txt_f="12577"> shows the percentage of patients with positive slide for asexual </offsets><italic><offsets xml_i="21289" xml_f="21303" txt_i="12577" txt_f="12591">P. falciparum </offsets></italic><offsets xml_i="21312" xml_f="21502" txt_i="12591" txt_f="12781">in both groups. By day three, four (1.8%) of 227 patients in the artemether-lumefantrine recipients and three (1.3%) of 238 artesunate-mefloquine recipients still had a positive blood film (</offsets><italic><offsets xml_i="21510" xml_f="21512" txt_i="12781" txt_f="12783">P </offsets></italic><offsets xml_i="21521" xml_f="21654" txt_i="12783" txt_f="12910">&gt; 0.05). Overall, 12.3 % of patients were anaemic (haematocrit &lt;30%) on admission, 10.8% in ALN group and 13.8% in MAS3 group (</offsets><italic><offsets xml_i="21662" xml_f="21664" txt_i="12910" txt_f="12912">P </offsets></italic><offsets xml_i="21673" xml_f="21921" txt_i="12912" txt_f="13160">= 0.33). The mean (SD) decrease in haematocrit value at day seven from baseline was greater in the group receiving MAS3 than in the ALN group: 9.3% (SD,11.5%; 95% CI, 7.7% to 10.9%) compared with 6.7% (SD, 11.4%; 95% CI, 5.1 to 8.3%) respectively (</offsets><italic><offsets xml_i="21929" xml_f="21931" txt_i="13160" txt_f="13162">P </offsets></italic><offsets xml_i="21940" xml_f="21949" txt_i="13162" txt_f="13171">= 0.023).</offsets></p><fig position="float" id="F1"><label><offsets xml_i="21990" xml_f="21998" txt_i="13172" txt_f="13180">Figure 1</offsets></label><caption><p><offsets xml_i="22018" xml_f="22078" txt_i="13180" txt_f="13237">Percentage of patients with fever (temperature &gt; 37.5°C).</offsets></p></caption><graphic xlink:href="1475-2875-4-46-1"></graphic></fig><fig position="float" id="F2"><label><offsets xml_i="22184" xml_f="22192" txt_i="13238" txt_f="13246">Figure 2</offsets></label><caption><p><offsets xml_i="22212" xml_f="22267" txt_i="13246" txt_f="13301">Percentage of patients with positive slide for asexual </offsets><italic><offsets xml_i="22275" xml_f="22289" txt_i="13301" txt_f="13315">P. falciparum </offsets></italic><offsets xml_i="22298" xml_f="22304" txt_i="13315" txt_f="13321">forms.</offsets></p></caption><graphic xlink:href="1475-2875-4-46-2"></graphic></fig><p><offsets xml_i="22376" xml_f="22419" txt_i="13322" txt_f="13365">During the 42-day follow-up period, 27 new </offsets><italic><offsets xml_i="22427" xml_f="22441" txt_i="13365" txt_f="13379">P. falciparum </offsets></italic><offsets xml_i="22450" xml_f="22547" txt_i="13379" txt_f="13476">infections occurred among artemether-lumefantrine and 24 among artesunate-mefloquine recipients (</offsets><italic><offsets xml_i="22555" xml_f="22557" txt_i="13476" txt_f="13478">P </offsets></italic><offsets xml_i="22566" xml_f="22584" txt_i="13478" txt_f="13493">&gt; 0.05) (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="22616" xml_f="22617" txt_i="13493" txt_f="13494">2</offsets></xref><offsets xml_i="22624" xml_f="22772" txt_i="13494" txt_f="13642">). The PCR-adjusted cure rates by day 42 were 98.8% (95% CI, 96.4% to 99.6%) in the ALN group and 96.3% (95% CI, 93.1% to 98.0%) in the MAS3 group (</offsets><italic><offsets xml_i="22780" xml_f="22782" txt_i="13642" txt_f="13644">P </offsets></italic><offsets xml_i="22791" xml_f="22925" txt_i="13644" txt_f="13778">= 0.08). PCR confirmed treatment failures were more likely in children aged below 15 years than in adults (RR, 5.1; 95% CI, 1.4–18.7; </offsets><italic><offsets xml_i="22933" xml_f="22935" txt_i="13778" txt_f="13780">P </offsets></italic><offsets xml_i="22944" xml_f="23566" txt_i="13780" txt_f="14396">= 0.006). The mean age was 13.6 years (n = 12; SD = 8.5) in patients with treatment failure and 23.7 years (n = 438; SD = 15.2) in successfully treated patients. In this trial, only age group was independently associated with treatment failure, but not other factors e.g. higher parasitaemia (&gt;10,000/μL); anaemia (haematocrit &lt;30%); fever (tympanic temp ≥ 37.5°C) on admission; sites; treatment groups; early vomiting (within one hour following drug administration). The mediantime to recrudescence was comparable for MAS3 group (21 days; n = 9; range, 14–28 days) and ALN group (28 days; n = 3; range, 21–42 days; </offsets><italic><offsets xml_i="23574" xml_f="23576" txt_i="14396" txt_f="14398">P </offsets></italic><offsets xml_i="23585" xml_f="23596" txt_i="14398" txt_f="14406">&gt; 0.05).</offsets></p></sec><sec><title><offsets xml_i="23618" xml_f="23648" txt_i="14408" txt_f="14438">Other parasitological findings</offsets></title><p><offsets xml_i="23659" xml_f="23692" txt_i="14439" txt_f="14472">Of 452 patients, 119 (26.3%) had </offsets><italic><offsets xml_i="23700" xml_f="23709" txt_i="14472" txt_f="14481">P. vivax </offsets></italic><offsets xml_i="23718" xml_f="23877" txt_i="14481" txt_f="14640">parasitaemia detected during follow up. There were significantly fewer cases of vivax malaria in the MAS3 group (29 of 227) than in the ALN group (90 of 225) (</offsets><italic><offsets xml_i="23885" xml_f="23887" txt_i="14640" txt_f="14642">P </offsets></italic><offsets xml_i="23896" xml_f="23942" txt_i="14642" txt_f="14685">&lt; 0.001). The median time to appearance of </offsets><italic><offsets xml_i="23950" xml_f="23959" txt_i="14685" txt_f="14694">P. vivax </offsets></italic><offsets xml_i="23968" xml_f="24090" txt_i="14694" txt_f="14816">parasitaemia was longer in the MAS3 group (40 days; range, 13–43 days) than in the ALN group (28 days; range, 14–43 days; </offsets><italic><offsets xml_i="24098" xml_f="24100" txt_i="14816" txt_f="14818">P </offsets></italic><offsets xml_i="24109" xml_f="24121" txt_i="14818" txt_f="14827">&lt; 0.001).</offsets></p><p><offsets xml_i="24128" xml_f="24625" txt_i="14828" txt_f="15325">Twenty patients (8.3%) in the artemether-lumefantrine group and 19 (7.9%) in the artesunate-mefloquine group had gametocytes detected during the first 3 days. All except one patient in ALN group cleared gametocytes within first week after start of treatment. After excluding these, gametocytes developed (between day 7 and 42) in 1.2% (3/241) of ALN group and 1.3 (3/240) of MAS3 group. The person-gametocyte weeks were low and similar: 2.7 (95% CI, 0.6–7.8) per 1000 person-weeks for both groups.</offsets></p></sec><sec><title><offsets xml_i="24647" xml_f="24661" txt_i="15327" txt_f="15341">Adverse events</offsets></title><p><offsets xml_i="24672" xml_f="24925" txt_i="15342" txt_f="15595">Both treatment regimens were well tolerated. No serious adverse events were reported. Overall, 5/242(2.1%) of the patients vomited one or more doses of medication in the ALN group and 2/242(0.8%) of the MAS3 treated patients (RR, 2.5; 95% CI, 0.5–12.7; </offsets><italic><offsets xml_i="24933" xml_f="24935" txt_i="15595" txt_f="15597">P </offsets></italic><offsets xml_i="24944" xml_f="25099" txt_i="15597" txt_f="15752">= 0.45). The rates of early vomiting (within one hour) of the drugs were very low (around 2%) and did not differ among groups (one in each group on day 2).</offsets></p><p><offsets xml_i="25106" xml_f="25409" txt_i="15753" txt_f="16053">The most commonly reported and possibly drug-related adverse events to both combination therapies were effects on the gastrointestinal (abdominal pain, anorexia, nausea, diarrhoea and late vomiting e.g. &gt;1 h after administration of treatment) and central nervous system (headache, dizziness). Figure </offsets><xref ref-type="fig" rid="F3"><offsets xml_i="25439" xml_f="25440" txt_i="16053" txt_f="16054">3</offsets></xref><offsets xml_i="25447" xml_f="25726" txt_i="16054" txt_f="16333"> shows the proportions of possibly drug-related adverse events of those who did not have those symptoms at admission during follow-up in both groups. Overall, there were less adverse events in ALN group compared to MAS3, though the differences were not statistically significant.</offsets></p><fig position="float" id="F3"><label><offsets xml_i="25767" xml_f="25775" txt_i="16334" txt_f="16342">Figure 3</offsets></label><caption><p><offsets xml_i="25795" xml_f="25849" txt_i="16342" txt_f="16396">Possibly drug-related adverse events (day 1 – day 42).</offsets></p></caption><graphic xlink:href="1475-2875-4-46-3"></graphic></fig></sec></sec><sec><title><offsets xml_i="25942" xml_f="25952" txt_i="16399" txt_f="16409">Discussion</offsets></title><p><offsets xml_i="25963" xml_f="26099" txt_i="16410" txt_f="16546">The loss of affordable effective antimalarial drugs to resistance represents a major threat to the people of malaria endemic countries [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="26130" xml_f="26131" txt_i="16546" txt_f="16547">1</offsets></xref><offsets xml_i="26138" xml_f="26350" txt_i="16547" txt_f="16759">]. Using ineffective drugs with high failure rates kills many and is unacceptable. A clear treatment policy and readiness to use the new, more effective artemisinin-based combination therapies (ACT) are crucial [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="26382" xml_f="26384" txt_i="16759" txt_f="16761">17</offsets></xref><offsets xml_i="26391" xml_f="26484" txt_i="16761" txt_f="16854">]. Along the north-western border of Thailand, where highly multi-drug resistant isolates of </offsets><italic><offsets xml_i="26492" xml_f="26506" txt_i="16854" txt_f="16868">P. falciparum </offsets></italic><offsets xml_i="26515" xml_f="26647" txt_i="16868" txt_f="17000">are found, artesunate-mefloquine combination therapy (MAS3) is the standard treatment regimen for uncomplicated falciparum malaria [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="26678" xml_f="26679" txt_i="17000" txt_f="17001">9</offsets></xref><offsets xml_i="26686" xml_f="26963" txt_i="17001" txt_f="17278">]. Early diagnosis and treatment with an artemisinin-based drug combination of very high efficacy that reduces gametocyte carriage, has led to a marked decline in the incidence of falciparum malaria and a reversal of the previous trend toward increasing mefloquine resistance [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="26995" xml_f="26997" txt_i="17278" txt_f="17280">18</offsets></xref><offsets xml_i="27004" xml_f="27658" txt_i="17280" txt_f="17934">]. Artemisinin derivatives will ensure rapid clinical and parasitological responses and are remarkably effective, hence clinical deterioration is extremely unusual. To optimize therapy, combination with a slower-acting antimalarial drug is required. Systematic use of ACT would help to delay the emergence of resistance if the drug was used widely. However, the continued use of mefloquine monotherapy or with only 2 days of artesunate in this region, provides persistent selective pressure to continue the evolution of mefloquine resistance, which could diminish the efficacy of the artesunate-mefloquine combination and that of artemether-lumefantrine.</offsets></p><p><offsets xml_i="27665" xml_f="27754" txt_i="17935" txt_f="18024">Artemether-lumefantrine has been introduced recently for oral treatment of uncomplicated </offsets><italic><offsets xml_i="27762" xml_f="27773" txt_i="18024" txt_f="18035">falciparum </offsets></italic><offsets xml_i="27782" xml_f="27959" txt_i="18035" txt_f="18212">malaria. In Thailand, several trials have been conducted with this combination. The six-dose schedule provides sustained blood lumefantrine levels and thus improved cure rates [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="27991" xml_f="27993" txt_i="18212" txt_f="18214">11</offsets></xref><offsets xml_i="28000" xml_f="28182" txt_i="18214" txt_f="18396">]. Lumefantrine is highly lipophilic and the oral bioavailability varies considerably between individuals and increases greatly if the drug is administered after a meal rich in fat [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="28214" xml_f="28216" txt_i="18396" txt_f="18398">19</offsets></xref><offsets xml_i="28223" xml_f="28225" txt_i="18398" txt_f="18400">].</offsets></p><p><offsets xml_i="28232" xml_f="28349" txt_i="18401" txt_f="18518">The present trial reconfirmed the efficacy of the six-dose regimen of artemether-lumefantrine given over three days [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="28381" xml_f="28383" txt_i="18518" txt_f="18520">20</offsets></xref><offsets xml_i="28390" xml_f="28556" txt_i="18520" txt_f="18686">]. Both treatments in this study cleared fever and parasitaemia promptly and reliably. Both treatments were well tolerated and highly effective. Importantly 2/3 less </offsets><italic><offsets xml_i="28564" xml_f="28573" txt_i="18686" txt_f="18695">P. vivax </offsets></italic><offsets xml_i="28582" xml_f="28641" txt_i="18695" txt_f="18754">infections and 12 days longer median time to appearance of </offsets><italic><offsets xml_i="28649" xml_f="28658" txt_i="18754" txt_f="18763">P. vivax </offsets></italic><offsets xml_i="28667" xml_f="28794" txt_i="18763" txt_f="18890">parasitaemia in the MAS3 group were most probably due to the longer terminal half-life of mefloquine compared to lumefantrine [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="28826" xml_f="28828" txt_i="18890" txt_f="18892">21</offsets></xref><offsets xml_i="28835" xml_f="28836" txt_i="18892" txt_f="18893">,</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="28868" xml_f="28870" txt_i="18893" txt_f="18895">22</offsets></xref><offsets xml_i="28877" xml_f="28997" txt_i="18895" txt_f="19015">]. More data on the safety and efficacy of artemether-lumefantrine in very small children and pregnant women are needed.</offsets></p></sec><sec><title><offsets xml_i="29019" xml_f="29041" txt_i="19017" txt_f="19039">Authors' contributions</offsets></title><p><offsets xml_i="29052" xml_f="29362" txt_i="19040" txt_f="19350">RH carried out the study and analyzed the data. RH, EAA, RMG, PS, TJ, NJW, FN conceived the study, participated in its design and co-ordination and contributed to draft the manuscript. LP, KLT assisted in collection of data. AB performed the PCR experiments. All authors read and approved the final manuscript.</offsets></p><table-wrap position="float" id="T2"><label><offsets xml_i="29410" xml_f="29417" txt_i="19351" txt_f="19358">Table 2</offsets></label><caption><p><offsets xml_i="29437" xml_f="29456" txt_i="19358" txt_f="19377">Treatment response.</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><offsets xml_i="29535" xml_f="29550" txt_i="19378" txt_f="19393">Treatment group</offsets></td><td align="left"><offsets xml_i="29572" xml_f="29586" txt_i="19394" txt_f="19408">ALN* (n = 245)</offsets></td><td align="left"><offsets xml_i="29608" xml_f="29624" txt_i="19409" txt_f="19425">MAS3** (n = 245)</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="29670" xml_f="29689" txt_i="19426" txt_f="19445">Compliance, no. (%)</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="29738" xml_f="29753" txt_i="19448" txt_f="19463">Completed day 7</offsets></td><td align="left"><offsets xml_i="29775" xml_f="29786" txt_i="19464" txt_f="19475">241 (99.6%)</offsets></td><td align="left"><offsets xml_i="29808" xml_f="29819" txt_i="19476" txt_f="19487">240 (99.2%)</offsets></td></tr><tr><td align="left"><offsets xml_i="29850" xml_f="29866" txt_i="19488" txt_f="19504">Completed day 28</offsets></td><td align="left"><offsets xml_i="29888" xml_f="29899" txt_i="19505" txt_f="19516">232 (95.9%)</offsets></td><td align="left"><offsets xml_i="29921" xml_f="29932" txt_i="19517" txt_f="19528">233 (96.3%)</offsets></td></tr><tr><td align="left"><offsets xml_i="29963" xml_f="29979" txt_i="19529" txt_f="19545">Completed day 42</offsets></td><td align="left"><offsets xml_i="30001" xml_f="30012" txt_i="19546" txt_f="19557">225 (93.0%)</offsets></td><td align="left"><offsets xml_i="30034" xml_f="30045" txt_i="19558" txt_f="19569">227 (93.4%)</offsets></td></tr><tr><td align="left"><offsets xml_i="30076" xml_f="30139" txt_i="19570" txt_f="19633">Cumulative proportion of patients with clinical failure, no (%)</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="30188" xml_f="30193" txt_i="19636" txt_f="19641">Day 7</offsets></td><td align="left"><offsets xml_i="30215" xml_f="30220" txt_i="19642" txt_f="19647">0 (0)</offsets></td><td align="left"><offsets xml_i="30242" xml_f="30247" txt_i="19648" txt_f="19653">0 (0)</offsets></td></tr><tr><td align="left"><offsets xml_i="30278" xml_f="30284" txt_i="19654" txt_f="19660">Day 28</offsets></td><td align="left"><offsets xml_i="30306" xml_f="30314" txt_i="19661" txt_f="19669">13 (5.6)</offsets></td><td align="left"><offsets xml_i="30336" xml_f="30344" txt_i="19670" txt_f="19678">14 (6.0)</offsets></td></tr><tr><td align="left"><offsets xml_i="30375" xml_f="30381" txt_i="19679" txt_f="19685">Day 42</offsets></td><td align="left"><offsets xml_i="30403" xml_f="30412" txt_i="19686" txt_f="19695">27 (12.0)</offsets></td><td align="left"><offsets xml_i="30434" xml_f="30443" txt_i="19696" txt_f="19705">24 (10.6)</offsets></td></tr><tr><td align="left"><offsets xml_i="30474" xml_f="30482" txt_i="19706" txt_f="19714">PCR, no.</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="30531" xml_f="30536" txt_i="19717" txt_f="19722">Novel</offsets></td><td align="left"><offsets xml_i="30558" xml_f="30560" txt_i="19723" txt_f="19725">23</offsets></td><td align="left"><offsets xml_i="30582" xml_f="30584" txt_i="19726" txt_f="19728">14</offsets></td></tr><tr><td align="left"><offsets xml_i="30615" xml_f="30627" txt_i="19729" txt_f="19741">Recrudescent</offsets></td><td align="left"><offsets xml_i="30649" xml_f="30650" txt_i="19742" txt_f="19743">2</offsets></td><td align="left"><offsets xml_i="30672" xml_f="30673" txt_i="19744" txt_f="19745">8</offsets></td></tr><tr><td align="left"><offsets xml_i="30704" xml_f="30724" txt_i="19746" txt_f="19766">Novel + recrudescent</offsets></td><td align="left"><offsets xml_i="30746" xml_f="30747" txt_i="19767" txt_f="19768">1</offsets></td><td align="left"><offsets xml_i="30769" xml_f="30770" txt_i="19769" txt_f="19770">1</offsets></td></tr><tr><td align="left"><offsets xml_i="30801" xml_f="30822" txt_i="19771" txt_f="19792">Indeterminate/missing</offsets></td><td align="left"><offsets xml_i="30844" xml_f="30845" txt_i="19793" txt_f="19794">1</offsets></td><td align="left"><offsets xml_i="30867" xml_f="30868" txt_i="19795" txt_f="19796">1</offsets></td></tr><tr><td align="left"><offsets xml_i="30899" xml_f="30931" txt_i="19797" txt_f="19829">PCR-adjusted cure rates, no. (%)</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="30980" xml_f="30985" txt_i="19832" txt_f="19837">Day 7</offsets></td><td align="left"><offsets xml_i="31007" xml_f="31014" txt_i="19838" txt_f="19845">0 (100)</offsets></td><td align="left"><offsets xml_i="31036" xml_f="31043" txt_i="19846" txt_f="19853">0 (100)</offsets></td></tr><tr><td align="left"><offsets xml_i="31074" xml_f="31080" txt_i="19854" txt_f="19860">Day 28</offsets></td><td align="left"><offsets xml_i="31102" xml_f="31110" txt_i="19861" txt_f="19869">2 (99.1)</offsets></td><td align="left"><offsets xml_i="31132" xml_f="31139" txt_i="19870" txt_f="19877">9(96.1)</offsets></td></tr><tr><td align="left"><offsets xml_i="31170" xml_f="31176" txt_i="19878" txt_f="19884">Day 42</offsets></td><td align="left"><offsets xml_i="31198" xml_f="31206" txt_i="19885" txt_f="19893">3 (98.8)</offsets></td><td align="left"><offsets xml_i="31228" xml_f="31236" txt_i="19894" txt_f="19902">9 (96.3)</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="31282" xml_f="31346" txt_i="19903" txt_f="19967">* ALN = artemether-lumefantrine, ** MAS3 = artesunate-mefloquine</offsets></p></table-wrap-foot></table-wrap></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank all the staff of the Shoklo Malaria Research Unit (SMRU) for their diligent work. This study was part of the Wellcome Trust-Mahidol University, Oxford Tropical Medicine Research Programme funded by the Wellcome Trust of Great Britain.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>Drug resistance in malaria</article-title><source>Br Med Bull</source><year>1998</year><volume>54</volume><fpage>703</fpage><lpage>715</lpage><pub-id pub-id-type="pmid">10326295</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>ter Kuile</surname><given-names>F</given-names></name><name><surname>Chongsuphajaisiddhi</surname><given-names>T</given-names></name><name><surname>Luxemburger</surname><given-names>C</given-names></name><name><surname>Webster</surname><given-names>HK</given-names></name><name><surname>Edstein</surname><given-names>M</given-names></name><name><surname>Phaipun</surname><given-names>L</given-names></name><name><surname>Thew</surname><given-names>KL</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>Mefloquine-resistant falciparum malaria on the Thai-Burmese border</article-title><source>Lancet</source><year>1991</year><volume>337</volume><fpage>1140</fpage><lpage>1143</lpage><pub-id pub-id-type="pmid">1674024</pub-id><pub-id pub-id-type="doi">10.1016/0140-6736(91)92798-7</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>Delaying antimalarial drug resistance with combination chemotherapy</article-title><source>Parassitologia</source><year>1999</year><volume>41</volume><fpage>301</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">10697872</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Looareesuwan</surname><given-names>S</given-names></name><name><surname>Olliaro</surname><given-names>P</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Chongsuphajaisiddhi</surname><given-names>T</given-names></name><name><surname>Sabcharoen</surname><given-names>A</given-names></name><name><surname>Thimasarn</surname><given-names>K</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Singhasivanon</surname><given-names>P</given-names></name><name><surname>Supavej</surname><given-names>S</given-names></name><name><surname>Khusmith</surname><given-names>S</given-names></name><name><surname>Wylings</surname><given-names>S</given-names></name><name><surname>Kanyok</surname><given-names>T</given-names></name><name><surname>Walsh</surname><given-names>D</given-names></name><name><surname>Leggat</surname><given-names>PA</given-names></name><name><surname>Doberstyn</surname><given-names>EB</given-names></name></person-group><article-title>Consensus recommendation on the treatment of malaria in Southeast Asia</article-title><source>Southeast Asian Journal of Tropical Medicine and Public Health</source><year>1998</year><volume>29</volume><fpage>355</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">9886127</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>R</given-names></name><name><surname>van Vugt</surname><given-names>M</given-names></name><name><surname>Phaipun</surname><given-names>L</given-names></name><name><surname>Luxemburger</surname><given-names>C</given-names></name><name><surname>Simpson</surname><given-names>J</given-names></name><name><surname>McGready</surname><given-names>R</given-names></name><name><surname>ter Kuile</surname><given-names>F</given-names></name><name><surname>Kham</surname><given-names>A</given-names></name><name><surname>Chongsuphajaisiddhi</surname><given-names>T</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name></person-group><article-title>Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives</article-title><source>Am J Trop Med Hyg</source><year>1999</year><volume>60</volume><fpage>547</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">10348227</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hien</surname><given-names>TT</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>Qinghaosu</article-title><source>Lancet</source><year>1993</year><volume>341</volume><fpage>603</fpage><lpage>608</lpage><pub-id pub-id-type="pmid">8094838</pub-id><pub-id pub-id-type="doi">10.1016/0140-6736(93)90362-K</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>Assessment of the pharmacodynamic properties of antimalarial drugs in vivo</article-title><source>Antimicrob Agents Chemother</source><year>1997</year><volume>41</volume><fpage>1413</fpage><lpage>1422</lpage><pub-id pub-id-type="pmid">9210658</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luxemburger</surname><given-names>C</given-names></name><name><surname>ter Kuile</surname><given-names>FO</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Dolan</surname><given-names>G</given-names></name><name><surname>Bradol</surname><given-names>JH</given-names></name><name><surname>Phaipun</surname><given-names>L</given-names></name><name><surname>Chongsuphajaisiddhi</surname><given-names>T</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malaria</article-title><source>Trans R Soc Trop Med Hyg</source><year>1994</year><volume>88</volume><fpage>213</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">8036679</pub-id><pub-id pub-id-type="doi">10.1016/0035-9203(94)90303-4</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Luxemburger</surname><given-names>C</given-names></name><name><surname>ter Kuile</surname><given-names>FO</given-names></name><name><surname>Woodrow</surname><given-names>C</given-names></name><name><surname>Eh</surname><given-names>JP</given-names></name><name><surname>Chongsuphajaisiddhi</surname><given-names>T</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination</article-title><source>J Infect Dis</source><year>1994</year><volume>170</volume><fpage>971</fpage><lpage>977</lpage><pub-id pub-id-type="pmid">7930743</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wernsdorfer</surname><given-names>WH</given-names></name><name><surname>Landgraf</surname><given-names>B</given-names></name><name><surname>Kilimali</surname><given-names>VA</given-names></name><name><surname>Wernsdorfer</surname><given-names>G</given-names></name></person-group><article-title>Activity of benflumetol and its enantiomers in fresh isolates of Plasmodium falciparum from East Africa</article-title><source>Acta Trop</source><year>1998</year><volume>70</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">9707360</pub-id><pub-id pub-id-type="doi">10.1016/S0001-706X(97)00141-1</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Vugt</surname><given-names>MV</given-names></name><name><surname>Wilairatana</surname><given-names>P</given-names></name><name><surname>Gemperli</surname><given-names>B</given-names></name><name><surname>Gathmann</surname><given-names>I</given-names></name><name><surname>Phaipun</surname><given-names>L</given-names></name><name><surname>Brockman</surname><given-names>A</given-names></name><name><surname>Luxemburger</surname><given-names>C</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Looareesuwan</surname><given-names>S</given-names></name></person-group><article-title>Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria</article-title><source>American Journal of Tropical Medicine and Hygiene</source><year>1999</year><volume>60</volume><fpage>936</fpage><lpage>942</lpage><pub-id pub-id-type="pmid">10403324</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luxemburger</surname><given-names>C</given-names></name><name><surname>Thwai</surname><given-names>KL</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Webster</surname><given-names>HK</given-names></name><name><surname>Kyle</surname><given-names>DE</given-names></name><name><surname>Maelankirri</surname><given-names>L</given-names></name><name><surname>Chongsuphajaisiddhi</surname><given-names>T</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name></person-group><article-title>The epidemiology of malaria in a Karen population on the western border of Thailand</article-title><source>Transactions of the Royal Society of Tropical Medicine and Hygiene</source><year>1996</year><volume>90</volume><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">8761562</pub-id><pub-id pub-id-type="doi">10.1016/S0035-9203(96)90102-9</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><article-title>Severe and complicated malaria. World Health Organization, Division of Control of Tropical Diseases</article-title><source>Trans R Soc Trop Med Hyg</source><year>1990</year><volume>84 Suppl 2</volume><fpage>1</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">2219249</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>van Vugt</surname><given-names>M</given-names></name><name><surname>Ezzet</surname><given-names>F</given-names></name></person-group><article-title>Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine</article-title><source>Clin Pharmacokinet</source><year>1999</year><volume>37</volume><fpage>105</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">10496300</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brockman</surname><given-names>A</given-names></name><name><surname>Paul</surname><given-names>RE</given-names></name><name><surname>Anderson</surname><given-names>TJ</given-names></name><name><surname>Hackford</surname><given-names>I</given-names></name><name><surname>Phaiphun</surname><given-names>L</given-names></name><name><surname>Looareesuwan</surname><given-names>S</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Day</surname><given-names>KP</given-names></name></person-group><article-title>Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand</article-title><source>American Journal of Tropical Medicine and Hygiene</source><year>1999</year><volume>60</volume><fpage>14</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">9988316</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jelinek</surname><given-names>T</given-names></name><name><surname>Kilian</surname><given-names>AH</given-names></name><name><surname>Westermeier</surname><given-names>A</given-names></name><name><surname>Proll</surname><given-names>S</given-names></name><name><surname>Kabagambe</surname><given-names>G</given-names></name><name><surname>Nothdurft</surname><given-names>HD</given-names></name><name><surname>von Sonnenburg</surname><given-names>F</given-names></name><name><surname>Loscher</surname><given-names>T</given-names></name></person-group><article-title>Population structure of recrudescent Plasmodium falciparum isolates from western Uganda</article-title><source>Trop Med Int Health</source><year>1999</year><volume>4</volume><fpage>476</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">10470338</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-3156.1999.00428.x</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Pongtavornpinyo</surname><given-names>W</given-names></name></person-group><article-title>The de novo selection of drug-resistant malaria parasites</article-title><source>Proc R Soc Lond B Biol Sci</source><year>2003</year><volume>270</volume><fpage>545</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1098/rspb.2002.2241</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>van Vugt</surname><given-names>M</given-names></name><name><surname>Price</surname><given-names>R</given-names></name><name><surname>Luxemburger</surname><given-names>C</given-names></name><name><surname>Thway</surname><given-names>KL</given-names></name><name><surname>Brockman</surname><given-names>A</given-names></name><name><surname>McGready</surname><given-names>R</given-names></name><name><surname>ter Kuile</surname><given-names>F</given-names></name><name><surname>Looareesuwan</surname><given-names>S</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study</article-title><source>Lancet</source><year>2000</year><volume>356</volume><fpage>297</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">11071185</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(00)02505-8</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ezzet</surname><given-names>F</given-names></name><name><surname>van Vugt</surname><given-names>M</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Looareesuwan</surname><given-names>S</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria</article-title><source>Antimicrob Agents Chemother</source><year>2000</year><volume>44</volume><fpage>697</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">10681341</pub-id><pub-id pub-id-type="doi">10.1128/AAC.44.3.697-704.2000</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Vugt</surname><given-names>M</given-names></name><name><surname>Looareesuwan</surname><given-names>S</given-names></name><name><surname>Wilairatana</surname><given-names>P</given-names></name><name><surname>McGready</surname><given-names>R</given-names></name><name><surname>Villegas</surname><given-names>L</given-names></name><name><surname>Gathmann</surname><given-names>I</given-names></name><name><surname>Mull</surname><given-names>R</given-names></name><name><surname>Brockman</surname><given-names>A</given-names></name><name><surname>White</surname><given-names>NJ</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name></person-group><article-title>Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria</article-title><source>Trans R Soc Trop Med Hyg</source><year>2000</year><volume>94</volume><fpage>545</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">11132386</pub-id><pub-id pub-id-type="doi">10.1016/S0035-9203(00)90082-8</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karbwang</surname><given-names>J</given-names></name><name><surname>Na-Bangchang</surname><given-names>K</given-names></name></person-group><article-title>Clinical application of mefloquine pharmacokinetics in the treatment of P falciparum malaria</article-title><source>Fundam Clin Pharmacol</source><year>1994</year><volume>8</volume><fpage>491</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">7721226</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ezzet</surname><given-names>F</given-names></name><name><surname>Mull</surname><given-names>R</given-names></name><name><surname>Karbwang</surname><given-names>J</given-names></name></person-group><article-title>Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients</article-title><source>Br J Clin Pharmacol</source><year>1998</year><volume>46</volume><fpage>553</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">9862244</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2125.1998.00830.x</pub-id></citation></ref></ref-list></back></article>